The Investigation of Bio-medical Science and Technology Innovation Service Platform in Guangzhou
Bibliographic record
Abstract
After the information industry, medicine industry has become an important driving force for the world's economic and social development, meanwhile, various types of innovation platform of science and technology has become an important support for the development of medicine industry. In this paper, based on in-depth investigation and analysis to innovation platform of science and technology in the field of medicine in Guangzhou, we clarified the basic situation of platform construction, operation and service, found problems of these platforms and put forward strategies and policy recommendations. Introduction Many countries put the industry as the priority to the development of strategic industries in the 21st century, as an important means to enhance the competitiveness of domestic. For instance, the United States took medicine industry as a new economic growth point, and implemented biotechnology industry incentives policy. Japan formulated the strategy of biological medicine industry state. The EU used 45% of the research and development funds for fields in FP6 (the sixth framework programme for research). The British government set up biotechnology coordinate and guide committee in 1981 and took various measures to promote the industry, universities and research institutions to increase investment in development research. India established department of and used 6000-7000 million dollars to the and pharmaceutical research. Stage of Development of Biological Industry Biological industry will gradually become an important driving force for world's economic and social development in the future. we divided the period of bio-industry into three stages, including the formation stage (1980-2000), growth stage (2000-2025) and the mature stage (2025-). Biological industry will truly become one of the leading industries of the world economy in 2020. The Features of the Biological and Health International Market The world drug market mainly concentrated in North America, Western Europe, Japan and Latin America in 2000, account for 85.2% of the world's total sales. As for national, the world pharmaceutical market mainly controlled by the following eight countries: The United States (40%), Japan (11%), German (6%), French( 6%), Italian (4%), the UK (3%), Canada (2%), and Spain (2%). Multinational companies control the international market. Enterprise merger and reorganization are successive. large scale of multinational pharmaceutical companies realize the complementary advantages in the restructuring, such as Glaxo Smithkline Beecham, Pfizer Warner Bothe, Hurst Barcelona, Astra Zeneca. The Trends of the Bio-medical Field Science and Technology Innovation Platform Modern technology becomes a booster of the pharmaceutical industry development. In the past decade, 60% 80% of the technology research and development activities focused in the field of medicine, research and development has become the main force of the new drug development. Natural medicine gradually becomes popular. With the advent of the return to natural boom, natural medicine for its unique efficacy and the side effects of smaller gradually was welcomed by patients, and its market share is increasing. OTC market is developing rapidly. The OTC is increasingly becoming an important part of global pharmaceutical market, and the cold cough medicine, gastrointestinal drugs, pain relievers, vitamins, antifungal drugs, smoking cessation drugs, anti-allergic become the most potential OTC varieties. New type of personalized service is more popular, communication in technology industry platform will be more in-depth and frequent. Technological Innovation Service Platform in China In China, over 80% of the bio-medical companies were established not more than 5 year. Their projects are still in the initial period and the average employee does not exceed 30 people, and their funds not more than 5 million. Enterprise’s main work is focused on the research and development of innovative products. Basically in the investment period, lacking capitals, researchers, development equipment and other hardware conditions become their fast-growing bottleneck, greatly hindering their ability to innovate. Therefore, it is very important to set up various forms of public service platform in various bio-medical medicine industries, and provide advanced equipment, technical support and other services for these companies. We find that the main characteristic and development trends of bio-medical innovation service platform are as follows in China: Diversification of investment; Construction based on the bio-medical industry chain; to activate the various types of innovation resources as the primary task; operating strategy of combination of marketization and public welfare. Technological Innovation Service Platform in Guangzhou In 2007, Guangzhou has become the national industry base city and the national medicine export base city with abundant medical resources, strong medicine culture, and solid industrial foundation. As a medical center and the pharmaceutical distribution center in southern China, Guangzhou medical resources ownership ranks third in the nation, and forms a relatively complete health care, health pension, health insurance, and other diversified services network, the medical service is radiating in Southern China area and Southeast Asia. In Guangzhou, Several new policies were formulated to accelerate the bio-medical development from the industrial development strategy, talent, capital, tax and other aspects, such as Opinions on promoting the Biotechnology Industry to accelerate development, Plan of Action on Biological Industry Development in Guangzhou(2010-2012), Guangzhou Bio-industry 12th Five-Year development Plan.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.010 |
| Science and technology studies | 0.000 | 0.007 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".